SGLT2is, and GLP-1 RAs in particular promote weight loss, and therefore especially may be of benefit, given that overweight and obesity is increasingly prevalent (62%) in individuals with type 1 diabetes [12]
Defrre S, Gonzlez-Ramos R, Lousse JC, Colette S, Donnez O, Donnez J, et al
Limited Visibility In a 1:1 matched case-control study performed by Chapman et al., patients getting GLP-1 RAs had significantly lower visibility scores during EGD and were 4.62 times more likely to have retained gastric contents compared to patients not on GLP-1 RAs ( p -value 0.025) [23]
Some researchers switch to a 3 mL reconstitution at this point for more manageable injection volumes
Ich nehme es jeden Tag morgens und Abends oder vor und nach dem Training